

KEY EUROPEAN PATENT FOR BREATHASSIST PLATFORM GRANTED

Melbourne, Monday 14 October 2013

Consegna Group Limited (ASX:CGP) (soon to be renamed Rhinomed Limited subject to shareholder approval,) advises that the European Patent Office has granted one of the company's core patents, application EP 1549379 entitled "A nasal cavity dilator."

The granted claims cover the company's BreatheAssist nasal dilation technology and the adjustability of the device, critical to comfort in each nostril.

Significantly, the patent also grants claims for a core element of Rhinomed's plans for the technology - the delivery of medicated vapour. The delivery of medicated vapour will be a one element that will drive the expansion of the technology, not only within sport and exercise, but also the growing health & wellbeing and drug delivery markets.

"Having patents granted in Europe for our BreatheAssist technology is a crucial commercial outcome for Rhinomed", said CEO Michael Johnson. "The European Patent now completes a global patent family and provides the Company with a sound IP position. We have been reviewing the company's IP position and putting in place specific strategies to strengthen it in key areas of value. The granting of this European patent is an important step in managing the existing patent portfolio."

Media Enquiries

Michael Johnson, CEO & Executive Director +61 (03) 9614 3663 mjohnson@rhinomed.com.au

About Consegna Group Limited (ASX:CGP)

Consegna (soon to be named Rhinomed Limited at the AGM) is a Melbourne based technology firm with a focus on nasal, respiratory and breathing management technologies. The company is monetising applications of its BreatheAssist technology portfolio in the Sport, Snoring, Olfactory, Sleep and Drug Delivery markets. It is launching its first Product the **Turbine™** nasal dilator later this year. For more information go to www.rhinomed.com.au

About the Turbine™

The **Turbine™** is a revolutionary product, which utilises the BreatheAssist technology and can deliver, to athletes, on average a 38% increase in airflow through the nasal passages. The **Turbine™** product range has been designed for both professional and amateur athletes participating in sports and fitness activities ranging from triathlon, cycling, running and non-impact sports to elite training environments, such as altitude training.